Suzhou Novoprotein Scientific Co (SHSE:688137) ROC (Joel Greenblatt) %: -3.51% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688137 Suzhou Novoprotein Scientific Co Ltd SHSE:688137
52 GF Score
Price ¥69.58
GF Value ¥37.43
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Suzhou Novoprotein Scientific Co ROC (Joel Greenblatt) %?

Suzhou Novoprotein Scientific Co SHSE:688137 +8.72% 52 ROC (Joel Greenblatt) % is -3.51% as of Mar. 2026. GuruFocus rates SHSE:688137 with a GF Score™ of 52/100 and a GF Value™ of ¥37.43 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,324 Biotechnology companies, Suzhou Novoprotein Scientific Co ranks better than 76.81% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Suzhou Novoprotein Scientific Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3.51%.

The historical rank and industry rank for Suzhou Novoprotein Scientific Co's ROC (Joel Greenblatt) % or its related term are showing as below:

SHSE:688137' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -268.19   Med: -1.41   Max: 645.28
Current: -5.02

During the past 8 years, Suzhou Novoprotein Scientific Co's highest ROC (Joel Greenblatt) % was 645.28%. The lowest was -268.19%. And the median was -1.41%.

SHSE:688137's ROC (Joel Greenblatt) % is ranked better than
76.81% of 1324 companies
in the Biotechnology industry
Industry Median: -306.72 vs SHSE:688137: -5.02

Suzhou Novoprotein Scientific Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Suzhou Novoprotein Scientific Co  (SHSE:688137) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Suzhou Novoprotein Scientific Co ROC (Joel Greenblatt) % Related Terms


Suzhou Novoprotein Scientific Co ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Suzhou Novoprotein Scientific Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Novoprotein Scientific Co ROC (Joel Greenblatt) % Chart

Suzhou Novoprotein Scientific Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial 147.67 42.70 2.04 -4.85 -4.99

Suzhou Novoprotein Scientific Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.33 -3.80 -2.86 -9.88 -3.51

SHSE:688137 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Suzhou Novoprotein Scientific Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Novoprotein Scientific Co ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Suzhou Novoprotein Scientific Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Suzhou Novoprotein Scientific Co's ROC (Joel Greenblatt) % falls into.


SHSE:688137
52GF Score
Suzhou Novoprotein Scientific Co Ltd SHSE:688137
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Novoprotein Scientific Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(61.768 + 63.316 + 1015.122) - (53.014 + 0 + 6.625)
=1080.567

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(64.414 + 70.511 + 920.132) - (62.925 + 0 + 6.958)
=985.174

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Suzhou Novoprotein Scientific Co for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-43.4/( ( (216.419 + max(1080.567, 0)) + (191.492 + max(985.174, 0)) )/ 2 )
=-43.4/( ( 1296.986 + 1176.666 )/ 2 )
=-43.4/1236.826
=-3.51 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -3.51% mean?
Suzhou Novoprotein Scientific Co (SHSE:688137) has a ROC (Joel Greenblatt) % of -3.51% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Suzhou Novoprotein Scientific Co and its competitors. According to the industry distribution chart, Suzhou Novoprotein Scientific Co ranks #307 out of 1324 companies in the Biotechnology industry, placing it in the top 23.2%.
Is Suzhou Novoprotein Scientific Co's ROC (Joel Greenblatt) % too high?
Suzhou Novoprotein Scientific Co's current ROC (Joel Greenblatt) % is -3.51%. Based on the distribution chart, Suzhou Novoprotein Scientific Co ranks #307 out of 1324 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Suzhou Novoprotein Scientific Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Novoprotein Scientific Co's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Novoprotein Scientific Co ranks #307 out of 1324 companies for ROC (Joel Greenblatt) %. This places Suzhou Novoprotein Scientific Co in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Suzhou Novoprotein Scientific Co and its competitors. Suzhou Novoprotein Scientific Co's current ROC (Joel Greenblatt) % is -3.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Novoprotein Scientific Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Novoprotein Scientific Co (SHSE:688137) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥37.43, compared to a current price of ¥69.58 — trading 85.9% above its estimated fair value. The current ROC (Joel Greenblatt) % is -3.51%. Suzhou Novoprotein Scientific Co's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Suzhou Novoprotein Scientific Co (SHSE:688137), the current ROC (Joel Greenblatt) % is -3.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suzhou Novoprotein Scientific Co (SHSE:688137) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Novoprotein Scientific Co stock appears to be overvalued. The current stock price of ¥69.58 is trading 85.9% above its estimated GF Value™ of ¥37.43. GuruFocus considers Suzhou Novoprotein Scientific Co to be Significantly Overvalued.

Key valuation signals for SHSE:688137:

  • ROC (Joel Greenblatt) %: -3.51%
  • GF Value™: ¥37.43 vs. price of ¥69.58 (85.9% above fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688137 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Suzhou Novoprotein Scientific Co Business Description

Address No. 228, Yunchuang Road, 3rd & 4th Floor, Wujiang Economic and Technological Development Zone, Jiangsu Province, Suzhou, CHN, 215299
Suzhou Novoprotein Scientific Co Ltd is a high-tech enterprise focusing on recombinant protein application solutions. Its main business is the research and development of target and cytokine proteins, recombinant antibodies, enzymes, and reagents, Production and sales, and providing related technical services.
52GF Score

Get the complete analysis for SHSE:688137

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥69.58
Price
¥37.43
GF Value